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As co-editors of Alzheimer’s Research and Th erapy we 
would like to highlight several of the major translational 
research advances that have occurred over the past year, 
during which a tremendous amount of superb science 
relevant to the study of Alzheimer’s disease (AD) has 
been published. Our selection is, of course, inﬂ uenced by 
our own biases, and selecting particular advances to 
highlight was challenging. Nevertheless, many major 
scientiﬁ c questions relevant to developing better thera-
pies and diagnostics for AD remain. Th e advances we 
have chosen to highlight represent evolving areas of 
research in AD that raise as many questions as they 
answer, but oﬀ er some promise that may help us to reach 
our shared goal of translating research advances into real 
advances that beneﬁ t patients.
Better cellular models of Alzheimer’s disease?
For many years the lack of truly faithful cellular and 
animal models of AD has imposed some limitation on 
what can be inferred from these experimental models. 
With the technological advances demonstrating that 
human ﬁ broblasts can be converted into pluripotent 
stem (iPS) cells and subsequently into neurons, and the 
promise of this technology to provide new cellular 
models of human neurodegenerative disease, it was only 
a matter of time for this technology to be applied to the 
study of AD.
Over the past year, the ﬁ rst of what are likely to be a 
plethora of studies examining culture models of AD 
based on neuronally diﬀ erentiated iPS cells derived from 
familial and sporadic AD patients and Down syndrome 
were published. Th e ﬁ rst of these demonstrated that 
ﬁ broblasts from familial AD patients with presenilin 1 or 
2 mutations showed altered processing of amyloid β 
protein precursor (APP) and increased production of 
total amyloid β protein (Aβ) with increased relative 
production of Aβ42 [1]. Th e second included neuronally 
diﬀ erentiated iPS cells from reprogrammed ﬁ broblasts of 
two APP gene duplication carriers, two patients with 
sporadic AD and two controls [2]. In the neuronally 
diﬀ erentiated iPS cell lines from familial and one of the 
two sporadic AD patients, there was higher secretion of 
Aβ40. A further ﬁ nding in these three AD cell lines 
provided a suggestion of interactions with mechanisms of 
tau pathology: higher levels of phospho-tau and active 
glycogen synthase kinase (GSK)3β. Th e third and most 
recent paper conducted similar studies using neuronally 
diﬀ erentiated iPS cells from Trisomy 21 patients [3]. 
When diﬀ erentiated, these cells showed increased pro-
duc tion of Aβ42, increased phospho-tau and perhaps 
most interesting, the accumulation of Aβ42 aggregates.
Although the alterations in APP and Aβ observed were 
largely anticipated, based on previous data from human 
ﬁ broblasts and other biological samples [4], the altera-
tions in tau and GSK3β activity are somewhat surprising. 
Even more surprising was the demonstration of extra-
cellular Aβ42 aggregates in long-term iPS Trisomy 21 
neuronal cultures. Indeed, no previous culture system to 
date has reproducibly produced such plaque-like aggre-
gates. If this is reproducible and conﬁ rmed to result in a 
plaque-like structure, it may be possible to utilize such 
cells to more precisely understand plaque formation 
under physiologic culture conditions.
Of course with any new technology there remain a 
number of concerns, and it is not clear whether issues of 
scale and reproducibility will enable this technology to 
totally overcome limitations of studying a degenerative 
brain disease in a culture dish. Th ough the consistency of 
the ﬁ ndings across the three studies is reassuring, they 
still only report on the phenotypes of a handful of cell 
lines from those at risk for AD. One future application 
that will be very intriguing is whether iPS cell technology 
may oﬀ er a way to obtain insights into biological 
mechanisms of genes implicated as risk modiﬁ ers in late 
onset AD [5,6]. Hopefully, such future studies will be 
conducted with appropriate experimental blinding and 
suﬃ  cient power to ensure that the results obtained are 
widely reproducible.© 2010 BioMed Central Ltd
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Insights into the mechanistic basis for the regional 
distribution and spread of AD pathology
Classic postmortem studies have framed the charac ter-
istic progression and regional distribution of tau and Aβ 
pathology in the brain. In AD, tau pathology charac-
teristically spreads from the entorhinal cortex into limbic 
and association cortices as AD evolves [7]. Several studies 
that have appeared this year provide mechanistic insights 
into the distribution and spread of tau pathology [8,9].
Th e microtubule associated protein tau has tradition-
ally been thought to be a cytoplasmic protein. It has been 
known for some time that soluble tau can be detected in 
CSF, but its presence in a body ﬂ uid was attributed to 
leakage from dead or dying cells [10]. More recent data 
from both cell culture studies and in vitro microdialysis 
suggest that tau and tau aggregates can be constitutively 
secreted from cells [11]. Moreover, there is evidence that 
extracellular tau aggregates can seed intracellular aggre-
gation. Two papers published in the last year suggest that 
tau secretion and subsequent seeding of aggregation can 
occur in vivo and account for the progression of tau 
pathology in vivo [8,9]. Both of these papers describe 
studies using transgenic mice expressing the fronto-
temporal dementia-associated tau P301L mutant in the 
entorrhinal cortex, and both demonstrated that tau 
pathology begins in the entorrhinal cortex in these mice 
but spreads along anatomically connected networks, 
possibly through synaptic connections. Th ese data are 
important conceptually as they provide further evidence 
that tau pathology in AD may spread through a prion-like 
conformation-dependent templating reaction mediated 
by release of tau aggregates from one cell and subsequent 
internalization by a neighbouring cell. Th ey also provide 
an explanation for the potential eﬃ  cacy of anti-tau 
immuno therapy [12]. Although it is possible that anti-tau 
anti bodies modulate tau pathology by somehow entering 
neurons and altering tau aggregation, these data would 
suggest that some anti-tau antibodies may block spread 
of tau pathology from one cell to another by targeting the 
extracellular tau transmitted from one cell to another.
Does epigenetic modifi cation off er new insights for 
developing treatment strategies?
Th e role of epigenetic mechanisms, that is, the ability of 
non-genetic factors to cause genes to express themselves 
diﬀ erently without changing their underlying DNA struc-
ture, is becoming apparent in an ever increasing number 
of biological and medical ﬁ elds and may oﬀ er insights 
into why therapeutic strategies targeting amyloid patho-
logy have been unsuccessful to date. An elegant study 
reported recently in Nature provides evidence that Aβ 
may constrain the expression of some memory- and 
learning-related genes [13]. After these have been 
‘switched oﬀ ’ by Aβ they cannot be ‘switched on’ again 
just by removing the Aβ. Th is process seems to be 
mediated via a histone deacetylase, HDAC2, which the 
authors have shown to be activated in brain tissue from 
both transgenic mouse models, where it reduced synaptic 
density and memory function, and human AD suﬀ erers. 
Th ey went on to show that inhibiting HDAC2 restored 
synaptic plasticity and improved some aspects of 
memory, although it did not boost the number of 
surviving neurons in the mice. Th e pathway is a complex 
one that also involves the glucocorticoid receptor, GR1.
Th e implied possibility of reversing pathology, in 
contrast to slowing decline, is an exciting one but needs 
further evaluation. HDAC inhibitors are already used or 
being explored in a number of conditions, for example, 
oncology, and some pharmaceutical companies are 
exploring their potential in AD. However, we also need to 
understand whether such drugs might aﬀ ect other 
important but unrelated aspects of genetic function. 
Roles of epigenetic mechanisms in aging and AD are 
likely to be a strong focus of future translational research.
Towards Alzheimer’s disease prevention
Over the past few years the challenges of disease modi ﬁ -
cation in symptomatic patients have become increasingly 
apparent. Preclinical studies almost in variably show 
diminishing eﬃ  cacy with increasing pathology at initia tion 
of treatment. Th ere have been several failed phase III 
clinical trials with disease modifying agents, though many 
of these agents were suboptimal with respect to potency, 
therapeutic window, or brain penetrance. More over, even 
phase II studies with more optimal disease modifying 
agents fail to show evidence for signiﬁ cant eﬃ  cacy.
Th us, a clinical highlight of the past year has been a 
renewed emphasis on designing and implementing more 
appropriate clinical trial methodology for evaluating 
disease-modifying treatment in AD. Editorials and 
reviews have emphasized that disease-modifying treat-
ment in established AD at the stage of dementia may be 
too late - the greatest beneﬁ t could come from preventing 
the chain of events that leads to neurodegeneration and 
irreversible structural changes in the brain [14-17]. 
Biomarkers exist that are able to identify AD pathology, 
particularly amyloid deposition, long before cognitive 
decline begins, and sensitive cognitive tests and 
paradigms using functional magnetic resonance imaging 
are showing alterations even during what has been 
termed ‘preclinical AD’ [16] and the ‘asymptomatic at 
risk’ individual [18] and new diagnostic research criteria 
have been proposed by two working groups.
Treatment trials are at an advanced level of planning in 
two groups of people at risk for AD. Programmes to 
clinically identify and characterize carriers of mutations 
in the presenilin or APP genes, and also systematic 
initiatives that aim to assess and evaluate biomarkers 
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during these presymptomatic stages are under way. Th e 
Alzheimer Prevention Initiative [17] has planned a 
clinical trial in a large population of presenilin 1 E280A 
mutation-carriers in Colombia, whose natural history 
and transition from asymptomatic through early 
symptoms and cognitive deﬁ cits to overt dementia has 
been precisely mapped in a landmark 15 year follow-up 
study [19]. Th e international Dominantly Inherited 
Alzheimer Network group has enrolled and characterized 
people with diﬀ erent APP and presenilin mutations [20] 
and is planning an intervention clinical trial in at risk 
carriers who test positive for amyloid biomarkers. 
Another initiative more closely relevant to sporadic AD 
proposes to identify amyloid carriers among elderly 
subjects who are not cognitively impaired and study their 
outcomes, using cognitive and imaging measures, over a 
period of two years [16].
In summary, this has been an exciting year for all of us 
working to improve treatment for people with AD. 
Greater understanding of the underlying pathological 
mecha nisms, gained from research using transgenic 
animals and new stem cell-based technologies, have 
revealed possible novel therapeutic strategies targeting 
the underlying pathologies, that is, both Aβ and tau 
pathology. Th ese developments are complemented by the 
move to identify pre-dementia AD and improve trial 
design. Together they provide hope for the future.
Abbreviations
Aβ, amyloid β protein; AD, Alzheimer ’s disease; APP, amyloid β protein 
precursor; GSK, glycogen synthase kinase; HDAC, histone deacetylase; iPS, 
induced pluripotent stem;
Competing interests
DG serves on data and safety monitoring boards for clinical trials for Janssen 
and Elan Pharmaceuticals and for Balance Pharmaceuticals. He is a consultant 
for Elan Pharmaceuticals, Phloronol, Inc., and United BioSource. TG has served 
on advisory boards related to preclinical studies for Janssen, Novarits, Bristol-
Myers Squib and Elan Pharmaceuticals. He has received sponsored research 
grants from Lundbeck and Myriad Pharmaceuticals in the past. GW has served 
on advisory boards to a number of pharmaceutical companies, including 
Jannsen, Shire Pharmaceuticals, Lundbeck, Cambridge Neurodiagnostics 
and Roche. He is a consultant to TauRx. DG, TG and GW are Editors-in-Chief of 
Alzheimer’s Research & Therapy and receive an annual honorarium.
Published: 18 May 2012
References
References indicated with an * are of special interest.
*1. Qiang L, Fujita R, Yamashita T, Angulo S, Rhinn H, Rhee D, Doege C, Chau L, 
Aubry L, Vanti WB, Moreno H, Abeliovich A: Directed conversion of 
Alzheimer’s disease patient skin fi broblasts into functional neurons. Cell 
2011, 146:359-371.
*2. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Heff eran MP, Van Gorp 
S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes 
AM, Koo EH, Goldstein LS: Probing sporadic and familial Alzheimer’s 
disease using induced pluripotent stem cells. Nature 2012, 482:216-220.
*3. Shi Y, Kirwan P, Smith J, MacLean G, Orkin SH, Livesey FJ: A human stem cell 
model of early Alzheimer’s disease pathology in Down syndrome. Sci 
Transl Med 2012, 4:124ra129.
4. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, 
Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, 
Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S: Secreted 
amyloid beta-protein similar to that in the senile plaques of Alzheimer’s 
disease is increased in vivo by the presenilin 1 and 2 and APP mutations 
linked to familial Alzheimer’s disease [see comments]. Nat Med 1996, 
2:864-870.
5. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, 
Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff -Radford 
NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, 
Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, 
Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, et al.: 
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are 
associated with late-onset Alzheimer’s disease. Nat Genet 2011, 43:436-441.
6. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, 
Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton 
A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, 
Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, 
Lynch A, Brown KS, Passmore PA, Craig D, et al.: Common variants at ABCA7, 
MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with 
Alzheimer’s disease. Nat Genet 2011, 43:429-435.
7. Braak H, Braak E: Frequency of stages of Alzheimer-related lesions in 
diff erent age categories. Neurobiol Aging 1997, 18:351-357.
*8. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff  K: Trans-synaptic 
spread of tau pathology in vivo. PLoS One 2012, 7:e31302.
*9. de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, 
Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, 
Hyman BT: Propagation of tau pathology in a model of early Alzheimer’s 
disease. Neuron 2012, 73:685-697.
10. Blennow K: Cerebrospinal fl uid protein biomarkers for Alzheimer’s disease. 
NeuroRx 2004, 1:213-225.
11. Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, 
Mandelkow EM, Diamond MI, Lee VM, Holtzman DM: In vivo microdialysis 
reveals age-dependent decrease of brain interstitial fl uid tau levels in 
P301S human tau transgenic mice. J Neurosci 2011, 31:13110-13117.
12. Sigurdsson EM: Immunotherapy targeting pathological tau protein in 
Alzheimer’s disease and related tauopathies. J Alzheimers Dis 2008, 
15:157-168.
*13. Gräff  J, Rei D, Guan JS, Wang WY, Seo J, Hennig KM, Nieland TJ, Fass DM, Kao 
PF, Kahn M, Su SC, Samiei A, Joseph N, Haggarty SJ, Delalle I, Tsai LH: 
An epigenetic blockade of cognitive functions in the neurodegenerating 
brain. Nature 2012, 483:222-226.
14. Golde TE, Schneider LS, Koo EH: Anti-abeta therapeutics in Alzheimer’s 
disease: the need for a paradigm shift. Neuron 2011, 69:203-213.
15. Sperling RA, Jack CR Jr, Aisen PS: Testing the right target and right drug at 
the right stage. Sci Transl Med 2011, 3:111cm133.
16. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, 
Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern 
Y, Yaff e K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH: 
Toward defi ning the preclinical stages of Alzheimer’s disease: 
recommendations from the National Institute on Aging-Alzheimer’s 
Association workgroups on diagnostic guidelines for Alzheimer’s disease. 
Alzheimers Dement 2011, 7:280-292.
*17. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, 
Quiroz YT, Kosik KS, Lopera F, Tariot PN: Alzheimer’s Prevention Initiative: 
a plan to accelerate the evaluation of presymptomatic treatments. 
J Alzheimers Dis 2011, 26 Suppl 3:321-329.
18. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-
Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, 
Jicha GA, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, 
Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P: Revising the defi nition 
of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010, 9:1118-1127.
*19. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez CM, Jaramillo-Elorza MC, 
Moreno S, Aguirre-Acevedo DC, Saldarriaga A, Lopera F: Pre-dementia 
clinical stages in presenilin 1 E280A familial early-onset Alzheimer’s 
disease: a retrospective cohort study. Lancet Neurol 2011, 10:213-220.
*20. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, 
Salloway S, Sperling RA, Windisch M, Xiong C: Autosomal-dominant 
Alzheimer’s disease: a review and proposal for the prevention of 
Alzheimer’s disease. Alzheimers Res Ther 2011, 3:1.
doi:10.1186/alzrt117
Cite this article as: Galasko D, et al.: Recent Alzheimer’s disease research 
highlights. Alzheimer’s Research & Therapy 2012, 4:14.
Galasko et al. Alzheimer’s Research & Therapy 2012, 4:14 
http://alzres.com/content/4/3/14
Page 3 of 3
